ALXN:NSD-Alexion Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 156.70

Change

0.00 (0.00)%

Market Cap

USD 34.27B

Volume

1.82M

Average Target Price

USD 154.95 (-1.12%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

N/A

USD55.27B 18.98 14.09
MRNA Moderna, Inc

N/A

USD51.30B N/A N/A
SGEN Seagen Inc

N/A

USD33.25B 70.15 66.51
RPRX Royalty Pharma plc

N/A

USD32.48B 22.60 11.76
BGNE BeiGene, Ltd

N/A

USD31.24B N/A N/A
GMAB Genmab A/S

N/A

USD28.71B 26.59 3.08
BNTX BioNTech SE

N/A

USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
INCY Incyte Corporation

N/A

USD19.83B 47.64 35.20

ETFs Containing ALXN

Symbol Name Weight Mer Price(Change) Market Cap
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.24B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD9.34M
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

N/A

USD10.37B
JKG iShares Morningstar Mid-C.. 0.00 % 0.25 %

N/A

USD0.80B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.06 %

N/A

USD0.16B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

N/A

USD0.51B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

N/A

USD0.03B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.27B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.19B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.27B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.29% 20% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.29% 20% F 26% F
Trailing 12 Months  
Capital Gain 38.34% 63% D 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.34% 63% D 71% C-
Trailing 5 Years  
Capital Gain -1.25% 49% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.25% 49% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -3.27% 37% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.27% 37% F 25% F
Risk Return Profile  
Volatility (Standard Deviation) 15.04% 97% A+ 78% C+
Risk Adjusted Return -21.77% 29% F 23% F
Market Capitalization 34.27B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.37 26% F 30% F
Price/Book Ratio 3.09 67% D+ 47% F
Price / Cash Flow Ratio 16.44 6% F 24% F
EV/EBITDA 33.83 15% F 26% F
Management Effectiveness  
Return on Equity 8.92% 95% A 74% C
Return on Invested Capital 17.95% 93% A 90% A-
Return on Assets 10.74% 98% A+ 96% A
Debt to Equity Ratio 21.07% 49% F 63% D
Technical Ratios  
Short Ratio 1.04 72% C- 71% C-
Short Percent 1.75% 85% B 67% D+
Beta 1.34 60% D- 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.